[HTML][HTML] The addition of gemtuzumab ozogamicin to induction chemotherapy in acute myeloid leukaemia: an individualpatient data meta-analysis of randomised trials …
RK Hills, S Castaigne, FR Appelbaum… - The Lancet …, 2014 - ncbi.nlm.nih.gov
Background Gemtuzumab Ozogamicin (GO) was the first example of antibody directed
chemotherapy in cancer and developed for Acute Myeloid Leukaemia. Its role has been …
chemotherapy in cancer and developed for Acute Myeloid Leukaemia. Its role has been …
[PDF][PDF] The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy in Acute Myeloid Leukaemia: An IndividualPatient Data Meta-analysis of Randomised …
Lancet Oncol, 2014 - academia.edu
NIH Public Access Page 1 The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy
in Acute Myeloid Leukaemia : An IndividualPatient Data Meta-analysis of Randomised Trials …
in Acute Myeloid Leukaemia : An IndividualPatient Data Meta-analysis of Randomised Trials …
[PDF][PDF] The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy in Acute Myeloid Leukaemia: An IndividualPatient Data Meta-analysis of Randomised …
Lancet Oncol, 2014 - researchgate.net
NIH Public Access Page 1 The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy
in Acute Myeloid Leukaemia : An IndividualPatient Data Meta-analysis of Randomised Trials …
in Acute Myeloid Leukaemia : An IndividualPatient Data Meta-analysis of Randomised Trials …